- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07645222
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
A PHASE Ib STUDY OF THE SAFETY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF HS-20122 COMBINED THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana
- Reclutamiento
- Ethics Committee of Sun Yat-sen University Cancer Center
-
Contacto:
- Ran Xu, MD
- Número de teléfono: 86-20-87343009
- Correo electrónico: llwyh@sysucc.org.cn
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Locally advanced or metastastic NSCLC;
- Received at least 1 line SoC,or treatment naïve;
- With at least 1 target lesion according to RECIST 1.1.
- Appropriate organ function
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1 and no deterioration within 2 weeks prior to the first dose.
- Minimum expected survival longer than 12 weeks
- Female subjects of childbearing potential are willing to take appropriate contraceptive measures and should not breastfeed from signing the informed consent form (ICF) through 6 months after the last dose; male subjects are willing to use barrier contraception (i.e., condom) from signing the ICF through 6 months after the last dose.
- Voluntarily participate in this clinical trial, understand the study procedures, and be able to sign written informed consent form.
Exclusion Criteria:
- Insufficient wash out duration of prior systemic anticancer therapy
- Local radiotherapy within 2 weeks prior to first dose of investigational drug
- Pleural/abdominal effusion requires clinical intervention
- Major surgery within 4 weeks prior to first dose of investigational drug
- History of drugs may prolong QT interval
- Have any grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior anti-tumor therapy (except alopecia and residual neurotoxicity).
- Presence of brain metastasis or carcinomatous meningtitis
- History of other primary malignancies
- Significant, uncontrolled, or active cardiovascular diseases
- Severe or poorly controlled diabetes
- Extremely obesity or emaciation
- Clinically significant bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose
- Severe arteriovenous thrombotic events (e.g., deep venous thrombosis, pulmonary embolism) within 3 months prior to the first dose
- Severe infection within 4 weeks
- History of systemic glucocorticoids over 28 days prior to first dose of investigational drug
- Presence of known active infectious diseases,
- Prensence of ophthalmological abnormalities.
17.Presence of hepatic encephalopathy, Hepato-renal Syndrome 18.Presence or history of confirmed or suspected ILD; 19.Prior history of significant neurological or mental disorders, including conditions that interfere with assessment, such as epilepsy, dementia, or major depressive disorder.
20.History of severe allergy, or history of hypersensitivity to any active or inactive ingredient of investigational drugs.
21.Presence of any conditions that jeopardize subject safety or interfere with study assessments as judged by the investigator.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: HS-20122+Aumolertinib
|
EGFR mut NSCLC, receive HS-20122+Aumolertinib
|
|
Experimental: HS-20122+Adbrelimab
|
EGFRwt NSCLC,receive HS-20122+Adbrelimab
|
|
Experimental: HS-20122+Adbrelimab+Platinum-based Chemo
|
EGFR wt NSCLC,receive HS-20122+Adbrelimab+ Platinum-based Chemo
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
EAE
Periodo de tiempo: Durante la duración completa de este ensayo, aproximadamente 2 años
|
incidencia de Eventos Adversos Graves evaluados por el Investigador, clasificados según CTCAE V5.0
|
Durante la duración completa de este ensayo, aproximadamente 2 años
|
|
RP2D for Combination
Periodo de tiempo: Through the full duration of this trial, approximately 2 years
|
To evaluate the potent and tolerated of combination(s) and dosage(s) of HS-20122 based therapy in subjects with locally advanced or metastatic NSCLC who have experienced disease progression on or after prior treatment, which suitable for a Phase II trial
|
Through the full duration of this trial, approximately 2 years
|
|
ORR
Periodo de tiempo: Through the full duration of this trial, approximately 2 years;
|
Investigator evaluated overall response rate, to evaluate the efficacy of each combination;
|
Through the full duration of this trial, approximately 2 years;
|
|
TEAE
Periodo de tiempo: Through the full duration of this trial, approximately 2 years;
|
incidence of Investigator evaluated Treatment Emerged Adverse Events, graded per CTCAE V5.0
|
Through the full duration of this trial, approximately 2 years;
|
|
TRAE
Periodo de tiempo: Through the full duration of this trial, approximately 2 years;
|
incidence of Investigator evaluated Treatment Related Adverse Events, graded per CTCAE V5.0
|
Through the full duration of this trial, approximately 2 years;
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Duration of Response
Periodo de tiempo: Through the full duration of this trial ,approximately 2 years
|
Investigator evaluated Duration of Response
|
Through the full duration of this trial ,approximately 2 years
|
|
Disease Control Rate
Periodo de tiempo: Through the full duration of this trial ,approximately 2 years;
|
Investigator evaluated Disease Control Rate
|
Through the full duration of this trial ,approximately 2 years;
|
|
Progression Free Survival
Periodo de tiempo: Through the full duration of this trial, approximately 2 years;
|
Investigator evaluated duration of Progression Free Survival
|
Through the full duration of this trial, approximately 2 years;
|
|
Overall Survival
Periodo de tiempo: Through the full duration of this trial ,approximately 2 years;
|
Investigator evaluated duration of Overall Survival
|
Through the full duration of this trial ,approximately 2 years;
|
|
PK parameter
Periodo de tiempo: Through the full duration of this trial, approximately 2 years;
|
blood concentration of combo agents
|
Through the full duration of this trial, approximately 2 years;
|
|
Immuogencity
Periodo de tiempo: Through the full duration of this trial ,approximately 2 years;
|
positive rate of drug specific antibody
|
Through the full duration of this trial ,approximately 2 years;
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- HS-20122-103
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .